Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2024-04, Vol.368, p.372-396
Main Authors: Zhang, Tingrui, Tai, Zongguang, Miao, Fengze, Zhang, Xinyue, Li, Jiadong, Zhu, Quangang, Wei, Hua, Chen, Zhongjian
Format: Article
Language:English
Subjects:
Adoptive cellular immunotherapy
antigens
CAR-M
CAR-NK
CAR-T
Cell- and Tissue-Based Therapy
Chimeric antigen receptor
Humans
immunosuppression
immunotherapy
Immunotherapy, Adoptive
neoplasms
Neoplasms - pathology
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
Solid tumor
T-Lymphocytes
Tumor Microenvironment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to the complex tumor microenvironment that affects the localization and killing ability of the CAR cells. Solid tumors with a strong immunosuppressive microenvironment and complex vascular system are unaffected by CAR cell infiltration and attack. To improve their efficacy toward solid tumors, CAR cells have been modified and upgraded by “decorating” and “pruning”. This review focuses on the structure and function of CARs, the immune cells that can be engineered by CARs and the transformation strategies to overcome solid tumors, with a view to broadening ideas for the better application of CAR cell therapy for the treatment of solid tumors. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2024.02.033